MedPath

The study on the efficacy and the mechanism of repetitive transcranial magnetic stimulation (rTMS) for mood disorders

Phase 2
Conditions
Major depression, bipolar disorder
Registration Number
JPRN-jRCTs072180045
Lead Sponsor
Tateishi Hiroshi
Brief Summary

rTMS treatment significantly improved depressive symptom scores and some subscales of cognitive dysfunction. The partial improvement of cognitive function and the decrease of serum IL-1beta showed a significant correlation.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
34
Inclusion Criteria

1.Patients with major depression or bipolar disorders who were ineffective for the treatment of more than one antidepressants
2.Written informed consent

Exclusion Criteria

Absolute contraindications are patients with metals in the brain, patients with intracardiac catheters, patients with high intracardiac pressure. Relative contraindications are epilepsy patients, patients with a history of intracranial lesions, oral history of drugs that reduce convulsion threshold, sleep deprivation, alcohol dependence, pregnant women, children, patients with severe heart disease. Regarding cerebrospinal fluid examination, patients with high risk such as bleeding tendency, heparin use, anesthesia allergy, cerebral hypertension etc., or patients judged inappropriate by the psychiatrist.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The efficacy of rTMS for patients with refractory mood disorders
Secondary Outcome Measures
NameTimeMethod
The changes of BDI , biomarkers in cerebrospinal fluid, blood and saliva, fractional anisotropy value, cerebral blood flow rate, cerebral cortex blood flow and oxygen consumption, frontal lobe function, electroencephalogram and their correlation.
© Copyright 2025. All Rights Reserved by MedPath